Bank of America Invests in Employee Health with GLP-1 Medications, Microsoft Relies on OpenAI

Bank of America is taking a proactive approach to employee health by covering the cost of GLP-1 weight loss medications, which can be expensive. The bank spends over $250 million annually on these medications and combines them with health coaching to help employees manage their weight and improve their overall well-being.

The decision is seen as a worthwhile investment for the bank's CEO Brian Moynihan, who believes that the treatments can have long-term benefits for employee health while reducing healthcare costs in the long run. This approach is part of the bank's broader efforts to prioritize employee wellness.

Meanwhile, Microsoft has released figures showing that its AI revenue from OpenAI accounted for 70% of its total AI business during the fiscal year, with a significant portion coming from their revenue-sharing agreement. This highlights the company's continued reliance on OpenAI despite efforts to diversify through investments in other AI companies and developing its own models.

In related news, Vital Signals has launched Signal Ring, a wearable device that claims to measure blood pressure directly from the finger without requiring calibration cuffs. The device is priced at $399 and has raised over $15 million in funding. However, researchers caution that independent validation and real-world testing are still needed before its readings can be considered reliable for individuals.